Richard F Little

Trials

Studies that name Richard F Little as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:54 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT04370834 · Tocilizumab for Patients With Cancer and COVID-19 Disease

  National Cancer Institute (NCI) · terminated · Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Pneumonia · principal investigator
• Ph2
  NCT00217503 · Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma

  National Cancer Institute (NCI) · completed · Lymphoma · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 03:54 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.